首页 > 最新文献

Kidney Research and Clinical Practice最新文献

英文 中文
Asymptomatic hematuria in children: Korean Society of Pediatric Nephrology recommendations for diagnosis and management. 儿童无症状血尿:韩国儿科肾脏病学会关于诊断和处理的建议。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-07 DOI: 10.23876/j.krcp.23.231
Eujin Park, Sang Woon Kim, Su Jin Kim, Minki Baek, Yo Han Ahn, Eun Mi Yang, Myung Hyun Cho, Hyun Kyung Lee, Kyoung Hee Han, Yae Lim Kim, Miyoung Choi, Hee Gyung Kang, Jin-Soon Suh

Hematuria is a relatively common condition among school-aged children. Because international guidelines for asymptomatic hematuria in children are unavailable, developing practical guidelines for the diagnosis and management of asymptomatic hematuria based on scientific evidence while considering real-world practice settings, values, and patient and physician preferences is essential. The Korean Society of Pediatric Nephrology developed clinical guidelines to address key questions regarding the diagnosis and management of asymptomatic hematuria in children.

在学龄儿童中,血尿是一种比较常见的症状。由于目前尚无针对儿童无症状血尿的国际指南,因此在考虑现实世界的实践环境、价值观以及患者和医生偏好的同时,基于科学证据制定实用的无症状血尿诊断和管理指南至关重要。韩国儿科肾脏病学会制定了临床指南,以解决有关儿童无症状血尿诊断和管理的关键问题。
{"title":"Asymptomatic hematuria in children: Korean Society of Pediatric Nephrology recommendations for diagnosis and management.","authors":"Eujin Park, Sang Woon Kim, Su Jin Kim, Minki Baek, Yo Han Ahn, Eun Mi Yang, Myung Hyun Cho, Hyun Kyung Lee, Kyoung Hee Han, Yae Lim Kim, Miyoung Choi, Hee Gyung Kang, Jin-Soon Suh","doi":"10.23876/j.krcp.23.231","DOIUrl":"10.23876/j.krcp.23.231","url":null,"abstract":"<p><p>Hematuria is a relatively common condition among school-aged children. Because international guidelines for asymptomatic hematuria in children are unavailable, developing practical guidelines for the diagnosis and management of asymptomatic hematuria based on scientific evidence while considering real-world practice settings, values, and patient and physician preferences is essential. The Korean Society of Pediatric Nephrology developed clinical guidelines to address key questions regarding the diagnosis and management of asymptomatic hematuria in children.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"565-574"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The current state of life expectancy of hemodialysis patients in Korea. 韩国血液透析患者的预期寿命现状。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-29 DOI: 10.23876/j.krcp.24.099
Seyoung Ryou, Hye Eun Yoon
{"title":"The current state of life expectancy of hemodialysis patients in Korea.","authors":"Seyoung Ryou, Hye Eun Yoon","doi":"10.23876/j.krcp.24.099","DOIUrl":"10.23876/j.krcp.24.099","url":null,"abstract":"","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"562-564"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac and kidney outcomes after sacubitril-valsartan therapy: recovery of cardiac function relative to kidney function decline. 萨库比特利-缬沙坦治疗后的心脏和肾脏预后:心功能的恢复与肾功能的下降相对应。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.23876/j.krcp.24.021
Hyo Jeong Kim, Eunji Yang, Hee Byung Koh, Jong Hyun Jhee, Hyeong Cheon Park, Hoon Young Choi

Background: Sacubitril-valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction (HFrEF). However, its long-term protective effects on cardiac function with concurrent acute kidney injury (AKI) remain unclear. This study investigated the recovery of cardiac function relative to kidney function decline.

Methods: A total of 512 patients with HFrEF who started sacubitril-valsartan or valsartan treatment were enrolled in cohort 1. Additionally, patients who experienced AKI and underwent follow-up transthoracic echocardiography were enrolled in cohort 2. In cohort 1, short- and long-term kidney outcomes were analyzed. For cohort 2, changes in cardiac function in relation to changes in kidney function after drug initiation were analyzed.

Results: The mean age of the patients was 68.3 ± 15.1 years, and 57.4% of the patients were male. AKI occurred in 15.9% of the sacubitril-valsartan group and 12.5% of the valsartan group. After AKI, 78.4% of patients in the sacubitril-valsartan group and 71.4% of those in the valsartan group underwent recovery. Furthermore, cardiovascular outcomes in patients who developed AKI after drug initiation were analyzed in cohort 2. The sacubitril-valsartan group showed a greater improvement in cardiac function compared with the valsartan group (12.4% ± 15.4% vs. 1.4% ± 5.7%, p = 0.046). The ratio of deltas of cardiac and kidney function in the sacubitril-valsartan and valsartan groups were -1.76 ± 2.58 and -0.20 ± 0.58, respectively (p = 0.03).

Conclusion: Patients with HFrEF treated with sacubitril-valsartan exhibited significant improvements in cardiovascular outcomes despite AKI.

背景沙库比妥-缬沙坦可降低射血分数降低型心力衰竭(HFrEF)患者的心血管死亡风险。然而,它对并发急性肾损伤(AKI)的心功能的长期保护作用仍不明确。本研究调查了相对于肾功能下降的心功能恢复情况:共有 512 名开始接受沙库比妥-缬沙坦或缬沙坦治疗的 HFrEF 患者被纳入队列 1。此外,曾发生 AKI 并接受经胸超声心动图随访的患者也被纳入队列 2。在队列 1 中,对短期和长期肾脏结果进行了分析。在队列 2 中,分析了用药后心功能变化与肾功能变化的关系:患者的平均年龄为 68.3 ± 15.1 岁,57.4% 的患者为男性。15.9%的沙库比特利-缬沙坦组和12.5%的缬沙坦组患者发生了AKI。发生 AKI 后,78.4% 的沙库比特利-缬沙坦组患者和 71.4% 的缬沙坦组患者恢复了健康。此外,队列 2 还分析了用药后发生 AKI 的患者的心血管预后。与缬沙坦组相比,sacubitril-缬沙坦组的心功能改善幅度更大(12.4% ± 15.4% vs. 1.4% ± 5.7%,p = 0.046)。沙库比特利-缬沙坦组和缬沙坦组的心功能和肾功能三角比分别为-1.76 ± 2.58和-0.20 ± 0.58(p = 0.03):结论:使用沙库比普利-缬沙坦治疗的高频低氧血症患者尽管出现了肾脏缺氧,但心血管预后仍有显著改善。
{"title":"Cardiac and kidney outcomes after sacubitril-valsartan therapy: recovery of cardiac function relative to kidney function decline.","authors":"Hyo Jeong Kim, Eunji Yang, Hee Byung Koh, Jong Hyun Jhee, Hyeong Cheon Park, Hoon Young Choi","doi":"10.23876/j.krcp.24.021","DOIUrl":"10.23876/j.krcp.24.021","url":null,"abstract":"<p><strong>Background: </strong>Sacubitril-valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction (HFrEF). However, its long-term protective effects on cardiac function with concurrent acute kidney injury (AKI) remain unclear. This study investigated the recovery of cardiac function relative to kidney function decline.</p><p><strong>Methods: </strong>A total of 512 patients with HFrEF who started sacubitril-valsartan or valsartan treatment were enrolled in cohort 1. Additionally, patients who experienced AKI and underwent follow-up transthoracic echocardiography were enrolled in cohort 2. In cohort 1, short- and long-term kidney outcomes were analyzed. For cohort 2, changes in cardiac function in relation to changes in kidney function after drug initiation were analyzed.</p><p><strong>Results: </strong>The mean age of the patients was 68.3 ± 15.1 years, and 57.4% of the patients were male. AKI occurred in 15.9% of the sacubitril-valsartan group and 12.5% of the valsartan group. After AKI, 78.4% of patients in the sacubitril-valsartan group and 71.4% of those in the valsartan group underwent recovery. Furthermore, cardiovascular outcomes in patients who developed AKI after drug initiation were analyzed in cohort 2. The sacubitril-valsartan group showed a greater improvement in cardiac function compared with the valsartan group (12.4% ± 15.4% vs. 1.4% ± 5.7%, p = 0.046). The ratio of deltas of cardiac and kidney function in the sacubitril-valsartan and valsartan groups were -1.76 ± 2.58 and -0.20 ± 0.58, respectively (p = 0.03).</p><p><strong>Conclusion: </strong>Patients with HFrEF treated with sacubitril-valsartan exhibited significant improvements in cardiovascular outcomes despite AKI.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":"43 5","pages":"614-625"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long non-coding RNA MEG3 silencing weakens high glucose-induced mesangial cell injury by decreasing LIN28B expression by sponging and sequestering miR-23c. 长非编码 RNA MEG3 沉默通过海绵化和封存 miR-23c 来减少 LIN28B 的表达,从而减轻高血糖诱导的间质细胞损伤。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2023-12-11 DOI: 10.23876/j.krcp.23.090
Lu Rong, Huanzhou Xue, Jianwei Hao, Jianjun Liu, Hao Xu

Background: Diabetic nephropathy (DN) is a common kidney disease in diabetic patients. Long non-coding RNA maternally expressed gene 3 (MEG3) and microRNA (miR)-23c are reported to be implicated in DN development. Nevertheless, it is unclear that the molecular mechanism between MEG3 and miR-23c in DN remains unclear.

Methods: Human mesangial cells (HMCs) were treated with high glucose (HG) to simulate the DN status in vitro. Expression of MEG3 and miR-23c was measured. Effects of MEG3 silencing on HG-stimulated HMC injury were determined. The relationship between MEG3 and miR-23c was verified by the dual-luciferase reporter and RNA immunoprecipitation assays.

Results: MEG3 was overexpressed in serums from DN patients and HG-stimulated HMCs. MEG3 knockdown weakened HG-stimulated HMC proliferation, extracellular matrix (ECM) accumulation, and inflammation. MEG3 regulated lin-28 homolog B (LIN28B) expression through adsorbing miR-23c. MiR-23c inhibitor reversed MEG3 knockdown-mediated effects on HG-stimulated HMC proliferation, ECM accumulation, and inflammation. LIN28B overexpression overturned miR-23c mimic-mediated effects on HG-stimulated HMC proliferation, ECM accumulation, and inflammation.

Conclusion: MEG3 regulated HMC injury via regulation of the miR-23c/LIN28B axis in DN, which can help us better understand the mechanism of DN mediated by MEG3.

背景:糖尿病肾病(DN糖尿病肾病(DN)是糖尿病患者常见的肾脏疾病。据报道,长非编码 RNA 母系表达基因 3(MEG3)和 microRNA(miR)-23c 与 DN 的发生有关。方法:用高葡萄糖(HG)处理人间质细胞(HMCs),在体外模拟 DN 状态。测量了 MEG3 和 miR-23c 的表达。测定了沉默 MEG3 对 HG 刺激的 HMC 损伤的影响。通过双荧光素酶报告和 RNA 免疫沉淀实验验证了 MEG3 和 miR-23c 之间的关系:结果:MEG3在DN患者和HG刺激的HMC血清中过表达。敲除 MEG3 会削弱 HG 刺激的 HMC 增殖、细胞外基质(ECM)积累和炎症反应。MEG3 通过吸附 miR-23c 调节 lin-28 homolog B(LIN28B)的表达。MiR-23c 抑制剂逆转了 MEG3 敲除介导的对 HG 刺激的 HMC 增殖、ECM 积累和炎症的影响。LIN28B过表达可逆转miR-23c模拟介导的对HG刺激的HMC增殖、ECM积累和炎症的影响:结论:MEG3通过调控miR-23c/LIN28B轴调节DN中的HMC损伤,这有助于我们更好地理解MEG3介导的DN机制。
{"title":"Long non-coding RNA MEG3 silencing weakens high glucose-induced mesangial cell injury by decreasing LIN28B expression by sponging and sequestering miR-23c.","authors":"Lu Rong, Huanzhou Xue, Jianwei Hao, Jianjun Liu, Hao Xu","doi":"10.23876/j.krcp.23.090","DOIUrl":"10.23876/j.krcp.23.090","url":null,"abstract":"<p><strong>Background: </strong>Diabetic nephropathy (DN) is a common kidney disease in diabetic patients. Long non-coding RNA maternally expressed gene 3 (MEG3) and microRNA (miR)-23c are reported to be implicated in DN development. Nevertheless, it is unclear that the molecular mechanism between MEG3 and miR-23c in DN remains unclear.</p><p><strong>Methods: </strong>Human mesangial cells (HMCs) were treated with high glucose (HG) to simulate the DN status in vitro. Expression of MEG3 and miR-23c was measured. Effects of MEG3 silencing on HG-stimulated HMC injury were determined. The relationship between MEG3 and miR-23c was verified by the dual-luciferase reporter and RNA immunoprecipitation assays.</p><p><strong>Results: </strong>MEG3 was overexpressed in serums from DN patients and HG-stimulated HMCs. MEG3 knockdown weakened HG-stimulated HMC proliferation, extracellular matrix (ECM) accumulation, and inflammation. MEG3 regulated lin-28 homolog B (LIN28B) expression through adsorbing miR-23c. MiR-23c inhibitor reversed MEG3 knockdown-mediated effects on HG-stimulated HMC proliferation, ECM accumulation, and inflammation. LIN28B overexpression overturned miR-23c mimic-mediated effects on HG-stimulated HMC proliferation, ECM accumulation, and inflammation.</p><p><strong>Conclusion: </strong>MEG3 regulated HMC injury via regulation of the miR-23c/LIN28B axis in DN, which can help us better understand the mechanism of DN mediated by MEG3.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"600-613"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Air pollution can affect kidney disease? Scientific evidence from epidemiology to experimental studies. 空气污染会影响肾病?从流行病学到实验研究的科学证据。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-12 DOI: 10.23876/j.krcp.24.103
Jiwoo Park, Whanhee Lee
{"title":"Air pollution can affect kidney disease? Scientific evidence from epidemiology to experimental studies.","authors":"Jiwoo Park, Whanhee Lee","doi":"10.23876/j.krcp.24.103","DOIUrl":"10.23876/j.krcp.24.103","url":null,"abstract":"","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"559-561"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of immunosuppressive agents on clinical outcomes in idiopathic membranous nephropathy. 免疫抑制剂对特发性膜性肾病临床疗效的影响。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2023-09-08 DOI: 10.23876/j.krcp.22.255
Ji-Young Choi, Ho Jun Chin, Hajeong Lee, Yena Jeon, Jeong-Hoon Lim, Hee-Yeon Jung, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, Sun-Hee Park

Background: Few comparative studies on the effects of immunosuppressants in patients with idiopathic membranous nephropathy have been conducted.

Methods: Data from 489 patients who received conservative treatment or immunosuppressants were retrospectively analyzed by propensity score matching. Primary outcomes were complete or partial remission (CR or PR) of proteinuria, and secondary outcomes were renal survival and infection.

Results: Of the 489 patients, 357 (73.0%) received immunosuppressants. Propensity score matching identified 82 patients from the conservative group and 82 patients in the immunosuppressant group. CR or PR at 12 months was significantly higher in the immunosuppressant group compared with the conservative group for the total population (p = 0.002) and the propensity score-matched population (p = 0.02). The use of immunosuppressants was significantly more effective with respect to achieving a CR or PR at 12 months in patients who were aged <65 years or female, or who had a proteinuria level of ≥4.0 g/g or an estimated glomerular filtration rate of ≥60 mL/min/1.73 m2 (p < 0.05). Renal survival was similar between patients receiving immunosuppressants and conservative treatment in both the total and matched populations. The immunosuppressant group (21.8%) had a significantly higher incidence of infections compared with the conservative group (13.6%) for the total population (p = 0.03), but statistical significance disappeared in the matched population (p > 0.99).

Conclusion: The remission rate was significantly higher in the immunosuppressant group than in the conservative group, particularly in the subgroup of patients who were young or female, or those with heavy proteinuria loads or good renal function.

背景:很少对免疫抑制剂对特发性膜性肾病患者的影响进行比较研究。方法:采用倾向评分匹配法对489例接受保守治疗或免疫抑制剂治疗的患者的数据进行回顾性分析。主要结果是蛋白尿的完全或部分缓解(CR或PR),次要结果是肾脏存活率和感染。结果:489例患者中,357例(73.0%)接受了免疫抑制剂治疗。倾向评分匹配确定了82名保守组患者和82名免疫抑制剂组患者。在总人群(p=0.002)和倾向评分匹配人群(p=0.02)中,免疫抑制剂组在12个月时的CR或PR显著高于保守组。在总人群中年龄为0.99的患者中,使用免疫抑制剂在12个月中实现CR或PR的效果显著更高免疫抑制剂组的缓解率明显高于保守组,尤其是在年轻或女性、蛋白尿量大或肾功能良好的患者亚组中。
{"title":"Effect of immunosuppressive agents on clinical outcomes in idiopathic membranous nephropathy.","authors":"Ji-Young Choi, Ho Jun Chin, Hajeong Lee, Yena Jeon, Jeong-Hoon Lim, Hee-Yeon Jung, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, Sun-Hee Park","doi":"10.23876/j.krcp.22.255","DOIUrl":"10.23876/j.krcp.22.255","url":null,"abstract":"<p><strong>Background: </strong>Few comparative studies on the effects of immunosuppressants in patients with idiopathic membranous nephropathy have been conducted.</p><p><strong>Methods: </strong>Data from 489 patients who received conservative treatment or immunosuppressants were retrospectively analyzed by propensity score matching. Primary outcomes were complete or partial remission (CR or PR) of proteinuria, and secondary outcomes were renal survival and infection.</p><p><strong>Results: </strong>Of the 489 patients, 357 (73.0%) received immunosuppressants. Propensity score matching identified 82 patients from the conservative group and 82 patients in the immunosuppressant group. CR or PR at 12 months was significantly higher in the immunosuppressant group compared with the conservative group for the total population (p = 0.002) and the propensity score-matched population (p = 0.02). The use of immunosuppressants was significantly more effective with respect to achieving a CR or PR at 12 months in patients who were aged <65 years or female, or who had a proteinuria level of ≥4.0 g/g or an estimated glomerular filtration rate of ≥60 mL/min/1.73 m2 (p < 0.05). Renal survival was similar between patients receiving immunosuppressants and conservative treatment in both the total and matched populations. The immunosuppressant group (21.8%) had a significantly higher incidence of infections compared with the conservative group (13.6%) for the total population (p = 0.03), but statistical significance disappeared in the matched population (p > 0.99).</p><p><strong>Conclusion: </strong>The remission rate was significantly higher in the immunosuppressant group than in the conservative group, particularly in the subgroup of patients who were young or female, or those with heavy proteinuria loads or good renal function.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"635-647"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41132358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized nutritional management in the transition from non-dialysis dependent chronic kidney disease to dialysis. 从非透析依赖型慢性肾病向透析过渡期间的个性化营养管理。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-10 DOI: 10.23876/j.krcp.23.142
Yoko Narasaki, Man Kit Siu, Matthew Nguyen, Kamyar Kalantar-Zadeh, Connie M Rhee

Dialysis has been the dominant treatment regimen in end-stage kidney disease as a means to remove uremic waste products and to maintain electrolyte, acid base, and fluid balance. However, given that dialysis may not always provide a survival benefit nor improved quality of life in certain subpopulations, there is growing recognition of the need for conservative and preservative management as an alternative treatment strategy for advanced chronic kidney disease (CKD). Personalized nutritional management tailored to patient's sociodemographics, social needs, psychological status, health literacy level, and preferences is a key component of conservative and preservative care, as well as in the management of patients transitioning from non-dialysis dependent CKD to dialysis. In this review, we discuss the nutritional and metabolic alterations that ensue in CKD; the rationale for low-protein diets in the conservative and preservative management of advanced CKD; the role of plant-based diets in kidney health; emerging data on dietary potassium and sodium intake on CKD outcomes; and the practical implementation of dietary interventions in advanced kidney disease.

透析一直是终末期肾病的主要治疗方案,是清除尿毒症废物、维持电解质、酸碱度和体液平衡的一种手段。然而,鉴于透析并不总能为某些亚人群带来生存益处或生活质量的改善,越来越多的人认识到有必要将保守和防腐管理作为晚期慢性肾病(CKD)的替代治疗策略。根据患者的社会人口统计学特征、社会需求、心理状态、健康知识水平和偏好量身定制的个性化营养管理是保守治疗和保留治疗的关键组成部分,也是对从非透析依赖型 CKD 向透析过渡的患者进行管理的关键组成部分。在这篇综述中,我们将讨论慢性肾脏病引起的营养和代谢改变;在晚期慢性肾脏病的保守和预防性治疗中使用低蛋白饮食的理由;植物性饮食在肾脏健康中的作用;有关膳食中钾和钠摄入量对慢性肾脏病预后影响的新数据;以及在晚期肾脏病中实际实施饮食干预的方法。
{"title":"Personalized nutritional management in the transition from non-dialysis dependent chronic kidney disease to dialysis.","authors":"Yoko Narasaki, Man Kit Siu, Matthew Nguyen, Kamyar Kalantar-Zadeh, Connie M Rhee","doi":"10.23876/j.krcp.23.142","DOIUrl":"10.23876/j.krcp.23.142","url":null,"abstract":"<p><p>Dialysis has been the dominant treatment regimen in end-stage kidney disease as a means to remove uremic waste products and to maintain electrolyte, acid base, and fluid balance. However, given that dialysis may not always provide a survival benefit nor improved quality of life in certain subpopulations, there is growing recognition of the need for conservative and preservative management as an alternative treatment strategy for advanced chronic kidney disease (CKD). Personalized nutritional management tailored to patient's sociodemographics, social needs, psychological status, health literacy level, and preferences is a key component of conservative and preservative care, as well as in the management of patients transitioning from non-dialysis dependent CKD to dialysis. In this review, we discuss the nutritional and metabolic alterations that ensue in CKD; the rationale for low-protein diets in the conservative and preservative management of advanced CKD; the role of plant-based diets in kidney health; emerging data on dietary potassium and sodium intake on CKD outcomes; and the practical implementation of dietary interventions in advanced kidney disease.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"575-585"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of current clinical practices and perceptions of patients and caregivers regarding Alport syndrome in South Korea. 调查韩国目前的临床实践以及患者和护理人员对 Alport 综合征的看法。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-24 DOI: 10.23876/j.krcp.23.260
Dabin Kim, Yo Han Ahn, Eunjeong Kang, Hajeong Lee, Min Hyun Cho, Hee Gyung Kang, Ji Hyun Kim

Background: Alport syndrome (AS) is a highly prevalent inherited kidney disease. Early diagnosis and intervention are crucial for improved kidney outcomes. This study evaluated awareness among Korean clinicians about AS and assessed the understanding of AS patients and caregivers.

Methods: An online survey targeting registered members of the Korean Society of Nephrology, the Korean Society of Pediatric Nephrology, AS patients, and their caregivers was conducted from January to April 2023.

Results: Out of 103 respondents, most had treated fewer than 10 AS patients. For certain kidney diseases, such as chronic kidney disease of unknown origin and focal segmental glomerulosclerosis, half or fewer considered AS as a potential diagnosis. Only half preferred immediate confirmation tests for suspected AS. Genetic testing was available at half of the medical centers, and fewer than half of the adult nephrologists considered genetic testing to be essential. While all the surveyed nephrologists would prescribe renin-angiotensin system blockade, the majority hesitated to initiate treatment. Vigilant genetic testing for donor candidates was not a common practice. While 80% of patients and 50% of caregivers understood the nature and prognosis of AS, they regretted the delayed diagnoses, insufficient explanations, and the absence of support groups.

Conclusion: Not rarely, AS patients may have been unrecognized as AS. Despite the noteworthy advancement of AS, the recent guidelines have not been widely adopted in clinical practice in Korea. Considering the challenges in Korea, there is an urgent need for locally tailored clinical practice recommendations and a dedicated registry to optimize patient outcomes.

背景:阿尔波特综合征(AS)是一种高发的遗传性肾病。早期诊断和干预对改善肾脏预后至关重要。本研究评估了韩国临床医生对AS的认识,并评估了AS患者和护理人员对AS的理解:方法:2023 年 1 月至 4 月,针对韩国肾脏病学会、韩国儿科肾脏病学会的注册会员、强直性脊柱炎患者及其护理人员开展了一项在线调查:在103名受访者中,大多数人治疗过不到10名强直性脊柱炎患者。对于某些肾脏疾病,如原因不明的慢性肾脏病和局灶节段性肾小球硬化症,半数或更少的人认为强直性脊柱炎是一种潜在的诊断。对于疑似强直性脊柱炎,只有一半的人倾向于立即进行确诊检查。半数医疗中心提供基因检测,但只有不到一半的成人肾病专家认为基因检测是必要的。虽然所有接受调查的肾病专家都会开肾素-血管紧张素系统阻断剂,但大多数人对是否启动治疗犹豫不决。对捐献者候选人进行严格的基因检测并不常见。虽然80%的患者和50%的护理人员了解强直性脊柱炎的性质和预后,但他们对诊断延迟、解释不足和缺乏支持团体表示遗憾:结论:强直性脊柱炎患者未被发现为强直性脊柱炎的情况并非罕见。尽管强直性脊柱炎的研究取得了显著进展,但最近的指南在韩国的临床实践中并未被广泛采用。考虑到韩国面临的挑战,亟需制定适合当地情况的临床实践建议和专门的登记册,以优化患者的治疗效果。
{"title":"Investigation of current clinical practices and perceptions of patients and caregivers regarding Alport syndrome in South Korea.","authors":"Dabin Kim, Yo Han Ahn, Eunjeong Kang, Hajeong Lee, Min Hyun Cho, Hee Gyung Kang, Ji Hyun Kim","doi":"10.23876/j.krcp.23.260","DOIUrl":"https://doi.org/10.23876/j.krcp.23.260","url":null,"abstract":"<p><strong>Background: </strong>Alport syndrome (AS) is a highly prevalent inherited kidney disease. Early diagnosis and intervention are crucial for improved kidney outcomes. This study evaluated awareness among Korean clinicians about AS and assessed the understanding of AS patients and caregivers.</p><p><strong>Methods: </strong>An online survey targeting registered members of the Korean Society of Nephrology, the Korean Society of Pediatric Nephrology, AS patients, and their caregivers was conducted from January to April 2023.</p><p><strong>Results: </strong>Out of 103 respondents, most had treated fewer than 10 AS patients. For certain kidney diseases, such as chronic kidney disease of unknown origin and focal segmental glomerulosclerosis, half or fewer considered AS as a potential diagnosis. Only half preferred immediate confirmation tests for suspected AS. Genetic testing was available at half of the medical centers, and fewer than half of the adult nephrologists considered genetic testing to be essential. While all the surveyed nephrologists would prescribe renin-angiotensin system blockade, the majority hesitated to initiate treatment. Vigilant genetic testing for donor candidates was not a common practice. While 80% of patients and 50% of caregivers understood the nature and prognosis of AS, they regretted the delayed diagnoses, insufficient explanations, and the absence of support groups.</p><p><strong>Conclusion: </strong>Not rarely, AS patients may have been unrecognized as AS. Despite the noteworthy advancement of AS, the recent guidelines have not been widely adopted in clinical practice in Korea. Considering the challenges in Korea, there is an urgent need for locally tailored clinical practice recommendations and a dedicated registry to optimize patient outcomes.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathological diagnosis of Alport syndrome. 阿尔波特综合征的病理诊断。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-23 DOI: 10.23876/j.krcp.24.063
Kyoung Bun Lee, Minsun Jung, Beom Jin Lim

Alport syndrome (AS) is a hereditary nephritis characterized by structural abnormalities in the glomerular basement membrane resulting from pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes. Conventional pathological evaluations reveal nonspecific light microscopic changes and diagnostic clues can be obtained through electron microscopy. Type IV collagen staining elucidates distinct patterns based on AS inheritance, aiding in subtype classification. However, limitations arise, particularly in autosomal dominant cases. Genetic testing, particularly next-generation sequencing, gains prominence due to its ability to identify diverse mutations within COL4A3, COL4A4, and COL4A5.

阿尔波特综合征(AS)是一种遗传性肾炎,其特征是由于 COL4A3、COL4A4 和 COL4A5 基因的致病变异导致肾小球基底膜结构异常。传统的病理评估显示的是非特异性的光镜变化,诊断线索可通过电子显微镜获得。IV 型胶原染色可根据 AS 的遗传性阐明不同的模式,有助于亚型分类。然而,这种方法也存在局限性,尤其是在常染色体显性遗传的病例中。基因检测,尤其是下一代测序,因其能够识别 COL4A3、COL4A4 和 COL4A5 中的各种突变而日益受到重视。
{"title":"Pathological diagnosis of Alport syndrome.","authors":"Kyoung Bun Lee, Minsun Jung, Beom Jin Lim","doi":"10.23876/j.krcp.24.063","DOIUrl":"https://doi.org/10.23876/j.krcp.24.063","url":null,"abstract":"<p><p>Alport syndrome (AS) is a hereditary nephritis characterized by structural abnormalities in the glomerular basement membrane resulting from pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes. Conventional pathological evaluations reveal nonspecific light microscopic changes and diagnostic clues can be obtained through electron microscopy. Type IV collagen staining elucidates distinct patterns based on AS inheritance, aiding in subtype classification. However, limitations arise, particularly in autosomal dominant cases. Genetic testing, particularly next-generation sequencing, gains prominence due to its ability to identify diverse mutations within COL4A3, COL4A4, and COL4A5.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GAIT-CKD (Gait Analysis using Artificial Intelligence for digital Therapeutics of patients with Chronic Kidney Disease): design and methods. GAIT-CKD(利用人工智能进行步态分析,为慢性肾病患者提供数字化治疗):设计与方法。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-22 DOI: 10.23876/j.krcp.23.273
Youngjin Song, In Cheol Jeong, Semin Ryu, Sunghan Lee, Jeonghwan Koh, Seokjue Jeong, Seongmin Park, Munsang Kim, Wonjun Lee, Okhyeon Rye, Yeojin Kim, Sanggyu Lee, Mooeob Ahn, Hyunsuk Kim

Background: Digital therapeutics are emerging as treatments for diseases and disabilities. In chronic kidney disease (CKD), gait is a potential biomarker for health status and intervention effectiveness. This study aims to analyze gait characteristics in CKD patients, providing baseline data for digital therapeutics development.

Methods: At baseline and after an 8-week intervention, we performed bioimpedance analysis measurements, the Timed Up and Go, Tinetti, and grip strength tests, and gait analysis in 217 healthy individuals and 276 patients with CKD. Demographic and clinical information was collected, including underlying diseases and medications, laboratory tests, and quality of life satisfaction surveys. Gait analysis was performed using skeleton data, which involved acquiring three-dimensional skeleton data of a walker using a single Kinect sensor. The performance of an artificial intelligence-based classification model in distinguishing between healthy individuals and those with CKD was then investigated. Simultaneously, inertia measurement unit analysis was conducted using measurements taken from the wrist and waist.

Results: Most subjects received a health intervention via an app, and their gait was assessed for improvements after an 8-week period. Incidents such as falls, fractures, hospitalizations, and deaths will be investigated in years 1 and 3.

Conclusion: This study confirmed that the gaits of healthy individuals and CKD patients were different, and the effect of the 8-week app-based health intervention will be analyzed. The study will yield important baseline data for creating digital therapeutics for CKD patients' diet/exercise in the future.

背景:数字疗法正在成为治疗疾病和残疾的新方法。在慢性肾脏病(CKD)中,步态是健康状况和干预效果的潜在生物标志物。本研究旨在分析 CKD 患者的步态特征,为数字疗法的开发提供基线数据:在基线和为期 8 周的干预后,我们对 217 名健康人和 276 名慢性肾脏病患者进行了生物阻抗分析测量、定时上下楼、Tinetti 和握力测试以及步态分析。此外,还收集了人口统计学和临床信息,包括基础疾病和药物、实验室检查和生活质量满意度调查。步态分析使用骨骼数据进行,包括使用单个 Kinect 传感器获取步行者的三维骨骼数据。然后研究了基于人工智能的分类模型在区分健康人和慢性肾脏病患者方面的性能。同时,还利用手腕和腰部的测量数据进行了惯性测量单元分析:大多数受试者通过一款应用程序接受了健康干预,并在 8 周后对他们的步态改善情况进行了评估。第 1 年和第 3 年将对跌倒、骨折、住院和死亡等事件进行调查:这项研究证实,健康人和慢性肾脏病患者的步态是不同的,并将对为期 8 周的基于应用程序的健康干预的效果进行分析。这项研究将为今后创建针对慢性肾脏病患者饮食/运动的数字疗法提供重要的基线数据。
{"title":"GAIT-CKD (Gait Analysis using Artificial Intelligence for digital Therapeutics of patients with Chronic Kidney Disease): design and methods.","authors":"Youngjin Song, In Cheol Jeong, Semin Ryu, Sunghan Lee, Jeonghwan Koh, Seokjue Jeong, Seongmin Park, Munsang Kim, Wonjun Lee, Okhyeon Rye, Yeojin Kim, Sanggyu Lee, Mooeob Ahn, Hyunsuk Kim","doi":"10.23876/j.krcp.23.273","DOIUrl":"https://doi.org/10.23876/j.krcp.23.273","url":null,"abstract":"<p><strong>Background: </strong>Digital therapeutics are emerging as treatments for diseases and disabilities. In chronic kidney disease (CKD), gait is a potential biomarker for health status and intervention effectiveness. This study aims to analyze gait characteristics in CKD patients, providing baseline data for digital therapeutics development.</p><p><strong>Methods: </strong>At baseline and after an 8-week intervention, we performed bioimpedance analysis measurements, the Timed Up and Go, Tinetti, and grip strength tests, and gait analysis in 217 healthy individuals and 276 patients with CKD. Demographic and clinical information was collected, including underlying diseases and medications, laboratory tests, and quality of life satisfaction surveys. Gait analysis was performed using skeleton data, which involved acquiring three-dimensional skeleton data of a walker using a single Kinect sensor. The performance of an artificial intelligence-based classification model in distinguishing between healthy individuals and those with CKD was then investigated. Simultaneously, inertia measurement unit analysis was conducted using measurements taken from the wrist and waist.</p><p><strong>Results: </strong>Most subjects received a health intervention via an app, and their gait was assessed for improvements after an 8-week period. Incidents such as falls, fractures, hospitalizations, and deaths will be investigated in years 1 and 3.</p><p><strong>Conclusion: </strong>This study confirmed that the gaits of healthy individuals and CKD patients were different, and the effect of the 8-week app-based health intervention will be analyzed. The study will yield important baseline data for creating digital therapeutics for CKD patients' diet/exercise in the future.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney Research and Clinical Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1